NEW DATA PRESENTED AT ASN KIDNEY WEEK SPOTLIGHT BAXTER’S SHARESOURCE TELEHEALTH PLATFORM AND AMIA APD SYSTEM IN SUPPORTING MORE EFFICIENT HOME DIALYSIS CARE

- Early data indicate Baxter’s SHARESOURCE telehealth platform is helping healthcare providers identify patient issues sooner; and providing better visibility to therapy adherence
- Dialysis clinic reports significantly reduced clinic training times due to Baxter’s AMIA APD system
- In total, Baxter presented 24 abstracts at Kidney Week to contribute to the latest scientific exchange about innovation and therapeutic practices for home, in-center and acute dialysis

DEERFIELD, Ill., Nov. 21, 2016 — Baxter International Inc. (NYSE: BAX), a global innovator in renal care for more than 60 years, presented data about the roles SHARESOURCE remote patient management platform and AMIA automated peritoneal dialysis (APD) system are playing in making home dialysis more efficient and supporting patient independence during the American Society of Nephrology’s (ASN) annual Kidney Week, Nov. 15-20 in Chicago.

Early data indicate how Baxter’s SHARESOURCE telehealth platform is helping physicians recognize adverse issues early, enabling faster treatment (Abstract #PO023); and how Baxter’s AMIA APD system, with voice-guided, patient-centric features, is helping a clinic significantly reduce training times by more than one day, per patient (Abstract #PO1047). In total, Baxter presented 24 abstracts across all renal modalities during Kidney Week to support scientific exchange during the meeting and increase the quality of care for patients with end-stage renal disease (ESRD).

“Data on the use of Baxter’s AMIA APD system and the SHARESOURCE telehealth platform tell us the technology is enhancing dialysis clinic efficiencies,” said Dheerendra Kommala, M.D., vice president, Medical Affairs, Baxter. “For the first time, physicians have more reliable visibility to their patient’s home therapy, which helps them identify potential clinical and therapy adherence issues sooner so that informed decisions can be addressed more quickly.”
The Baxter SHARESOURCE platform data was discussed in a case study from the Geneva University Hospital in Geneva, Switzerland. Healthcare providers at the hospital offer SHARESOURCE with Baxter’s HOMECHOICE CLARIA APD system. For one patient, the hospital initially observed no remote patient management alerts and normal PD cycle volume profiles. Then, SHARESOURCE conveyed red flag alerts of prolonged drain times for the patient, which allowed the hospital clinicians to make an early diagnosis and surgically reposition a displaced catheter. Catheter malposition and dysfunction is one of the leading causes for dropout from PD and transfer to hemodialysis (HD)\(^1\,^2\).

Additionally, a simulation study of twelve APD patient profiles suggests remote management of APD patients through telehealth can save approximately $22,000 in total healthcare resources (Abstract #PO483). The study identified saved healthcare resources associated with treatment non-adherence, fluid overload, missing data and other issues, enabling earlier medical intervention to help avoid complications and treatment drop-out.

New data presented on Baxter’s AMIA APD system also indicated how a clinic was able to provide more efficient training for patients, helping those on AMIA to go home at least one day sooner than on the legacy APD system. These conclusions were reached in a retrospective review of patients on AMIA and the Baxter HOMECHOICE system by the Icahn School of Medicine, Mount Sinai, Renal Division in New York.

### About AMIA and HOMECHOICE CLARIA with SHARESOURCE

AMIA was designed to allow patients to administer their own PD therapy in the home setting with intuitive features, such as voice guidance, a touchscreen control panel and the SHARESOURCE remote patient management platform. AMIA also is up to 40 percent smaller and 30 percent lighter than other cyclers on the market, and features a folding design when the touch screen is not in use\(^3\,^4\).

SHARESOURCE allows healthcare providers to securely view their patients’ recently completed home dialysis-related treatment data that is automatically collected after each PD session. Healthcare providers can then act on this information by remotely adjusting their patients’ home device settings without requiring them to travel to the clinic.

AMIA with SHARESOURCE is available in the United States and is currently being used by more than 1,000 ESRD patients to manage therapy. The SHARESOURCE remote patient
management platform is also available outside the United States on Baxter’s HOMECHOICE CLARIA system, which is currently being used by more than 1,300 patients to conduct home therapy. Baxter’s SHARESOURCE telehealth platform recently reached a milestone of helping healthcare providers manage about 200,000 PD treatments performed in patients’ homes with either AMIA or HOMECHOICE CLARIA.

Rx Only. For safe and proper use of the devices mentioned herein, refer to the complete instructions in the Operator’s Manual.

About Baxter International Inc.

Baxter provides a broad portfolio of essential renal and hospital products, including home, acute and in-center dialysis; sterile IV solutions; infusion systems and devices; parenteral nutrition; biosurgery products and anesthetics; and pharmacy automation, software and services. The company’s global footprint and the critical nature of its products and services play a key role in expanding access to healthcare in emerging and developed countries. Baxter’s employees worldwide are building upon the company’s rich heritage of medical breakthroughs to advance the next generation of healthcare innovations that enable patient care.

This release includes forward-looking statements concerning Baxter’s AMIA and HOMECHOICE CLARIA APD systems and the SHARESOURCE remote patient management platform, including anticipated benefits associated with their use. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: satisfaction of regulatory and other requirements; actions of regulatory bodies and other governmental authorities; product quality, manufacturing or supply issues; patient safety issues; changes in law and regulations; breaches or failures of the company’s information technology systems; and other risks identified in Baxter’s most recent filing on Form 10-K and other SEC filings, all of which are available on Baxter’s website. Baxter does not undertake to update its forward-looking statements.

# # #

Baxter, Amia, HomeChoice Claria and Sharesource are registered trademarks of Baxter International Inc.